Tyra Biosciences Inc. Common Stock (TYRA)
Stock · NASDAQ · Health Care
$18.52as of 10/16/2026
Price chart
Active signals
TYRA Signal Track Record
How signals performed across all stocks →What TYRA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 52 | +0.5% | 50% | September 4, 2026 |
| Bollinger Band Breakdown | 21 | +4.0% | 57% | September 9, 2026 |
| Bollinger Band Breakout | 20 | -0.7% | 50% | September 4, 2026 |
| 200-Day Moving Average TouchActive now | 9 | +16.5% | 78% | June 11, 2026 |
| Any 20-session window (baseline) | +1.3% | 53% |
Computed by MarketWall from daily closing prices since June 30, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TYRA
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candid…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 87
- Website
- tyra.bio/
Fundamentals
- 1-day range
- $20.95$22.32
- Market cap
- $1.61B
- P/E (trailing)
- —
- P/E (forward)
- -7.58
- EPS (trailing)
- $-2.39
- Dividend yield
- —
- Beta
- 0.62
- Avg. volume
- 850.5K
Forecasts
11 analyst ratings
Tyra Biosciences Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- TYRATyra Biosciences Inc. Common Stock$18.52▼ 2.73%Market cap $1.61BP/E —$12.96$40.65
- MRVIMaravai LifeSciences Holdings Inc. Class A Common Stock$6.79▼ 3.96%Market cap $1.61BP/E —$2.55$9.42
- ANABAnaptysBio Inc. Common Stock$46.61▼ 4.31%Market cap $1.62BP/E 7.14$20.18$72.36
- AAPGAscentage Pharma Group International American Depository Shares$15.37▲ 4.63%Market cap $1.60BP/E —$27.12$75.1
- TRAXFirst Tracks Biotherapeutics Inc. Ordinary Shares$34.46▼ 4.38%Market cap $1.58BP/E —$14.72$49.91
- INVAInnoviva Inc. Common Stock$20.78▼ 0.38%Market cap $1.56BP/E 4.25$16.52$25.15
- ZYMEZymeworks Inc. Common Stock$25.03▼ 2.80%Market cap $1.69BP/E —$16$31.34
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TYRA Tyra Biosciences Inc. Common Stock | $1.61B | — | $18.52 | ▼ 2.73% | $12.96$40.65 |
| MRVI Maravai LifeSciences Holdings Inc. Class A Common Stock | $1.61B | — | $6.79 | ▼ 3.96% | $2.55$9.42 |
| ANAB AnaptysBio Inc. Common Stock | $1.62B | 7.14 | $46.61 | ▼ 4.31% | $20.18$72.36 |
| AAPG Ascentage Pharma Group International American Depository Shares | $1.60B | — | $15.37 | ▲ 4.63% | $27.12$75.1 |
| TRAX First Tracks Biotherapeutics Inc. Ordinary Shares | $1.58B | — | $34.46 | ▼ 4.38% | $14.72$49.91 |
| INVA Innoviva Inc. Common Stock | $1.56B | 4.25 | $20.78 | ▼ 0.38% | $16.52$25.15 |
| ZYME Zymeworks Inc. Common Stock | $1.69B | — | $25.03 | ▼ 2.80% | $16$31.34 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- Verjee Rehan · May 28, 2026 · Grant13.2K
- Rothenberg Stephen Michael · May 28, 2026 · Grant13.2K
- Jake Simson · May 28, 2026 · Grant13.2K
- Susan Moran · May 28, 2026 · Grant13.2K
- Adele M. Gulfo · May 28, 2026 · Grant13.2K
- RA Capital Healthcare Fund LP · May 28, 2026 · Grant13.2K
- Robert J. More · May 28, 2026 · Grant13.2K
- Warner Douglas J · May 5, 2026 · Grant85.0K
- Warner Douglas J · May 5, 2026 · Grant25.0K
- Rueb Yuliya · May 5, 2026 · Grant28.0K
- Rueb Yuliya · May 5, 2026 · Grant8.3K
- Ashar Bhavesh · May 5, 2026 · Grant50.3K
- Ashar Bhavesh · May 5, 2026 · Grant15.0K
- Harris Todd · May 5, 2026 · Grant265.0K
- Harris Todd · May 5, 2026 · Grant79.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 65.92M
- Total value held
- $2.48B
- Institutional holders
- 157
- Unknown12.20M
- Unknown7.75M
- Unknown4.06M
- Unknown3.89M
- Unknown3.82M
- Unknown3.58M
- Unknown3.25M
- Unknown2.48M
- Unknown2.22M
- Unknown2.05M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Tyra Biosciences (TYRA) Faces Turnaround After 27% Drop
Tyra Biosciences stock has fallen 27% over the past four weeks, a decline that has pushed the price near key support levels. Some market observers suggest this drop may signal a potential turnaround for the company. The average analyst target price remains significantly higher than the current trading range, reflecting a gap between current sentiment and long-term expectations.
Tyra Biosciences (TYRA) Faces Turnaround After 27% Drop. Tyra Biosciences stock has fallen 27% over the past four weeks, a decline that has pushed the price near key support levels. Some market observers suggest this drop may signal a potential turnaround for the company. The average analyst target price remains significantly higher than the current trading range, reflecting a gap between current sentiment and long-term expectations.